According to results from a biomarker biopsy study conducted as part of the ongoing phase I investigation of MPDL3280A, patients who reacted to therapy were more likely to have tumor-infiltrating cells and tumor PD-L1 expression to begin with [131]. Here, CD274 is linked to neoplasm.